Clinical Trial

SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis

Study acronym: SAMeMASLDc-02
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety, feasibility, and preliminary effects of S-adenosyl-L-methionine (SAMe) compared with placebo in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis. Investigators will assess whether treatment is associated with changes in liver-related clinical measures, biologic markers, and other study outcomes relevant to disease progression. The goal of this study is to generate early data to determine whether SAMe should be studied further as a potential therapeutic strategy in patients with MASLD cirrhosis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-22.
Trial Details
NCT Number NCT07495995
Lead Sponsor Cedars-Sinai Medical Center
Conditions Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Enrollment 94 participants
Start Date 2026-04-15
Primary Completion 2030-12-31 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-31